In 2007, Lama and her colleagues published another discovery about the stem cells, revealing that the cells reside in the transplanted organs, independent of their more commonly known association with bone marrow. That study led to the further exploration of the cells’ involvement with chronic transplant rejection.
The new findings also have the potential to spur research that will help people suffering from other types of lung disease, such as idiopathic pulmonary fibrosis, known as IPF.
Having the biomarker will also allow researchers to readily identify a population of patients ideal for testing new drug interventions and therapies.
“By the time we usually diagnose BOS, there’s already been a huge decline in lung function,” Lama says. “If we can find the disease early, we can potentially do something about it.”
Methodology: Mesenchymal stromal cells were measured in 405 bronchoalveolar lavage fluid samples obtained from 162 lung transplant recipients and patients were observed for BOS development.
The research was supported by grants from the National Institutes of Health, American Thoracic Society and Scleroderma Research Foundation.
Source-Medindia